- About this Journal ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 850150, 8 pages
Survival of Dopaminergic Amacrine Cells after Near-Infrared Light Treatment in MPTP-Treated Mice
1Discipline of Anatomy & Histology F13, The University of Sydney, Sydney, NSW 2006, Australia
2Discipline of Physiology F13, The University of Sydney, Sydney, NSW 2006, Australia
3Institute of Ophthalmology, University College London, London EC1VGEL, UK
4Department of Optometry and Visual Science, City University, London EC1V7DD, UK
Received 3 February 2012; Accepted 1 April 2012
Academic Editors: G. Meco, J.-I. Satoh, K. F. So, and F. G. Wouterlood
Copyright © 2012 Cassandra Peoples et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. O. Rinne, “Nigral degeneration in Parkinson's disease,” Movement Disorders, vol. 8, no. 1, supplement, pp. S31–S35, 1993.
- K. D. Desmet, D. A. Paz, J. J. Corry et al., “Clinical and experimental applications of NIR-LED photobiomodulation,” Photomedicine and Laser Surgery, vol. 24, no. 2, pp. 121–128, 2006.
- M. R. Hamblin and T. N. Demidova, “Mechanisms of low level light therapy,” in Mechanisms for Low-Light Therapy, vol. 6140 of Proceedings of the SPIE, pp. 1–12, January 2006.
- V. E. Shaw, S. Spana, K. Ashkan et al., “Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment,” Journal of Comparative Neurology, vol. 518, no. 1, pp. 25–40, 2010.
- C. Peoples, S. Spana, K. Ashkan et al., “Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease,” Parkinsonism and Related Disorders, vol. 18, no. 5, pp. 469–476, 2012.
- J. Ma, V. E. Shaw, and J. Mitrofanis, “Does melatonin help save dopaminergic cells in MPTP-treated mice?” Parkinsonism and Related Disorders, vol. 15, no. 4, pp. 307–314, 2009.
- V. E. Shaw, K. A. Keay, K. Ashkan, A. L. Benabid, and J. Mitrofanis, “Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus,” Parkinsonism and Related Disorders, vol. 16, no. 5, pp. 338–344, 2010.
- G. E. Meredith, S. Totterdell, M. Beales, and C. K. Meshul, “Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease,” Experimental Neurology, vol. 219, no. 1, pp. 334–340, 2009.
- B. A. Wallace, K. Ashkan, C. E. Heise et al., “Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys,” Brain, vol. 130, no. 8, pp. 2129–2145, 2007.
- W. G. Tatton, M. M. Kwan, M. C. Verrier, N. A. Seniuk, and E. Theriault, “MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells,” Brain Research, vol. 527, no. 1, pp. 21–31, 1990.
- F. Nagel, M. Bähr, and G. P. H. Dietz, “Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins,” Brain Research Bulletin, vol. 79, no. 5, pp. 303–309, 2009.
- P. A. Lapchak, J. Wei, and J. A. Zivin, “Transcranial infrared laser therapy improves clinical eating scores after embolic strokes in rabbits,” Stroke, vol. 35, no. 8, pp. 1985–1988, 2004.
- L. DeTaboada, S. Ilic, S. Leichliter-Martha, U. Oron, A. Oron, and J. Streeter, “Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke,” Lasers in Surgery and Medicine, vol. 38, no. 1, pp. 70–73, 2006.
- A. Oron, U. Oron, J. Chen et al., “Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits,” Stroke, vol. 37, no. 10, pp. 2620–2624, 2006.
- Y. Lampl, J. A. Zivin, M. Fisher et al., “Infrared laser therapy for ischemic stroke: a new treatment strategy—results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1),” Stroke, vol. 38, no. 6, pp. 1843–1849, 2007.
- F. Schiffer, A. L. Johnston, C. Ravichandran, et al., “Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety,” Behavioral and Brain Functions, vol. 5, pp. 1–13, 2009.
- M. A. Naeser, A. Saltmarche, M. H. Krengel, M. R. Hamblin, and J. A. Knight, “Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports,” Photomedicine and Laser Surgery, vol. 29, no. 5, pp. 351–358, 2011.
- J. Stone, The Whole Mount Handbook. A Guide to the Preparation and Analysis of Retinal Whole Mounts, Maitland, Sydney, Australia, 1981.
- C. Versaux-Botter, J. Nguyen-Legros, A. Vigny, and N. Raoux, “Morphology, density and distribution of tyrosine hydroxylase-like immunoreactive cells in the retina of mice,” Brain Research, vol. 301, no. 1, pp. 192–197, 1984.
- I. Wulle and J. Schnitzer, “Distribution and morphology of tyrosine hydroxylase-immunoreactive neurons in the developing mouse retina,” Developmental Brain Research, vol. 48, no. 1, pp. 59–72, 1989.
- J. Mitrofanis, A. Vigny, and J. Stone, “Distribution of catecholaminergic cells in the retina of the rat, guinea pig, cat, and rabbit: independence from ganglion cell distribution,” Journal of Comparative Neurology, vol. 267, no. 1, pp. 1–14, 1988.
- R. Natoli, Y. Zhu, K. Valter, S. Bisti, J. Eells, and J. Stone, “Gene and noncoding RNA regulation underlying photoreceptor protection: microarray study of dietary antioxidant saffron and photobiomodulation in rat retina,” Molecular Vision, vol. 16, pp. 1801–1822, 2010.
- Z. X. Qu, N. H. Neff, and M. Hadjiconstantinou, “MPP+ depletes retinal dopamine and induces D-1 receptor supersensitivity,” European Journal of Pharmacology, vol. 148, no. 3, pp. 453–455, 1988.
- J. T. Eells, M. M. Henry, P. Summerfelt et al., “Therapeutic photobiomodulation for methanol-induced retinal toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 6, pp. 3439–3444, 2003.
- J. Nguyen-Legros, C. Botteri, and L. H. Phuc, “Morphology of primate's dopaminergic amacrine cells as revealed by TH-like immunoreactivity on retinal flat-mounts,” Brain Research, vol. 295, no. 1, pp. 145–153, 1984.
- C. Harnois, G. Marcotte, and T. Di Paolo, “Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence,” Experimental Eye Research, vol. 49, no. 4, pp. 543–552, 1989.
- M. F. Ghilardi, E. Chung, I. Bodis-Wollner, M. Dvorzniak, A. Glover, and M. Onofrj, “Systemic 1-methyl, 4-phenyl, 1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates,” Life Sciences, vol. 43, no. 3, pp. 255–262, 1988.
- A. P. Mariani, N. H. Neff, and M. Hadjiconstantinou, “1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment decreases dopamine and increases lipofuscin in mouse retina,” Neuroscience Letters, vol. 72, no. 2, pp. 221–226, 1986.
- Y. Takatsuna, E. Adachi-Usami, H. Ino, and T. Chiba, “Effects of MPTP on the mouse retina,” Journal of Japanese Ophthalmological Society, vol. 96, no. 6, pp. 767–775, 1992.
- C. Wong, T. Ishibashi, G. Tucker, and D. Hamasaki, “Responses of the pigmented rabbit retina to NMPTP, a chemical inducer of Parkinsonism,” Experimental Eye Research, vol. 40, no. 4, pp. 509–519, 1985.
- A. Björklund, C. Rosenblad, C. Winkler, and D. Kirik, “Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease,” Neurobiology of Disease, vol. 4, no. 3-4, pp. 186–200, 1997.
- A. Nicotra and S. H. Parvez, “Apoptotic molecules and MPTP-induced cell death,” Neurotoxicology and Teratology, vol. 24, no. 5, pp. 599–605, 2002.
- K. Fujita, Y. Nakabeppu, and M. Noda, “Therapeutic effects of hydrogen in animal models of Parkinson's disease,” Parkinson's Disease, vol. 2011, Article ID 307875, 9 pages, 2011.
- A. Schober, “Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP,” Cell and Tissue Research, vol. 318, no. 1, pp. 215–224, 2004.
- D. C. German, K. F. Manaye, P. K. Sonsalla, and B. A. Brooks, “Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism: sparing of calbindin-D(28k)-containing cells,” Annals of the New York Academy of Sciences, vol. 648, pp. 42–62, 1992.
- E. Fitzpatrick, K. Ashkan, B. A. Wallace, A. L. Benabid, and J. Mitrofanis, “Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats,” Anatomy and Embryology, vol. 210, no. 2, pp. 101–123, 2005.
- Z. Cheng, Y. M. Zhong, and X. L. Yang, “Expression of the dopamine transporter in rat and bullfrog retinas,” NeuroReport, vol. 17, no. 8, pp. 773–777, 2006.
- E. Hirsch and Y. A. Agid, “Melanised dopainergic neurones are differentially susceptible to degeneration in Parkinson disease,” Nature Clinical Practice Neurology, vol. 324, pp. 345–348, 1988.
- I. Ishimoto, H. Kiyama, K. Hamano et al., “Co-localization of adrenergic receptors and vitamin-D-dependent calcium-binding protein (calbindin) in the dopaminergic amacrine cells of the rat retina,” Neuroscience Research, vol. 7, no. 3, pp. 257–263, 1989.
- G. Tosini, N. Pozdeyev, K. Sakamoto, and P. M. Iuvone, “The circadian clock system in the mammalian retina,” BioEssays, vol. 30, no. 7, pp. 624–633, 2008.
- M. Martín, M. Macías, J. León, G. Escames, H. Khaldy, and D. Acuña-Castroviejo, “Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria,” International Journal of Biochemistry and Cell Biology, vol. 34, no. 4, pp. 348–357, 2002.
- J. C. Mayo, R. M. Sainz, I. Antolín, F. Herrera, V. Martin, and C. Rodriguez, “Melatonin regulation of antioxidant enzyme gene expression,” Cellular and Molecular Life Sciences, vol. 59, no. 10, pp. 1706–1713, 2002.
- R. L. Yeager, D. A. Oleske, R. A. Sanders, J. B. Watkins, J. T. Eells, and D. S. Henshel, “Melatonin as a principal component of red light therapy,” Medical Hypotheses, vol. 69, no. 2, pp. 372–376, 2007.